Your DNA might hold vital information that your doctor overlooks when prescribing medication.
A recent study, released on Wednesday in Science Translational Medicine, revealed that nearly 25% of participants had been given a medication that could have necessitated an alternative drug or dosage based on their genetic makeup.
Conducted by researchers from the University of Pittsburgh, the study assessed 16 genes that influence how individuals metabolize medications.
The research analyzed DNA samples from 98,590 participants enrolled in the National Institutes of Health’s All of Us Research Program, correlating them with available medical records.
Each individual possessed at least one genetic variation pertinent to their drug responses, with the average participant harboring nine. Among those with both genetic and clinical data, 24.4% had been prescribed at least one medication that, according to genetic guidelines, should have been substituted with a different option or adjusted in dosage.
Nevertheless, the study did not analyze whether patients experienced adverse effects or if their medications were less effective due to their genetic characteristics.
Dr. Philip Empey, the senior author and an associate professor at the University of Pittsburgh’s School of Pharmacy, suggests that understanding a patient’s genetic background could minimize the trial-and-error approach often involved in medication prescriptions.
“Anything we can do to better anticipate the most effective medications and appropriate dosages can help reduce that trial and error,” he remarked.

A pharmacist organizes medications at a pharmacy in Vancouver in October 2022. Genetic variations may influence how patients respond to specific medications, potentially prompting doctors to modify the dosage or select a different drug. (Darryl Dyck/The Canadian Press)
Selecting the appropriate medication
Medications such as omeprazole and pantoprazole for acid reflux, along with atorvastatin for cholesterol, were frequently prescribed to participants whose genetic profiles suggested possible adjustments in treatment.
Empey notes that certain genetic variations can elevate the likelihood of muscle issues when patients are administered statins like atorvastatin, which are intended to lower heart attack or stroke risks.
This insight enables medical professionals to choose alternative medications or modify treatment plans.
“It empowers clinicians to make informed choices, allowing them to say, ‘Perhaps we should avoid that cholesterol medication. Maybe we initiate treatment more cautiously, or monitor for specific toxicities more diligently,'” said Empey.
In some cases, the stakes can be considerably higher.
Experts consulted by CBC News indicate that genetic testing can pinpoint patients who are unlikely to react positively to clopidogrel (Plavix), a medication used to avert blood clots following cardiac stenting, thus permitting doctors to opt for a different treatment.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health. He emphasizes that while genetic testing can guide medication selection, other factors like diet, lifestyle, and existing medications must also be taken into account. (CBC)
A guideline, not a certainty
Dr. James Kennedy, who heads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), stated that the findings of the study were not unexpected. However, he was particularly impressed with its representation of genetic diversity, especially among individuals of African descent.
Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had previously experimented with two or three antidepressants without achieving satisfactory outcomes.
He notes that approximately 8% to 10% of individuals metabolize certain widely prescribed antidepressants at an unusually slow rate, leading to medication accumulation and possible side effects.
Kennedy asserts that genetic testing is particularly beneficial for patients who have faced challenges with multiple medications.
However, he cautions that DNA testing alone cannot predict a patient’s response to a specific medication. Factors such as other medications, tobacco use, and dietary habits must also be taken into account.
“We explain, ‘Here’s your genetic blueprint, your tendencies, and now let’s discuss all the additional factors you need to consider before making a final decision,'” he explained.
A 2023 European clinical trial referenced in the study discovered that conducting genetic tests prior to prescribing specific medications reduced adverse drug reactions. Nevertheless, implementing routine testing in Canada presents challenges.

A researcher at the University of Calgary demonstrates a diagnostic kit utilized to detect genetic variations in February 2024. Although such testing could aid doctors in customizing medications for individual patients, financial and logistical barriers have hindered its broader application in Canada. (Jeff McIntosh/The Canadian Press)
Challenges in widespread testing across Canada
Dr. Jacob Udell, a cardiologist in Toronto, acknowledged the impressive nature of the study, particularly due to the genetic diversity of its participants. However, he noted that few healthcare providers in Canada or the U.S. routinely test for genetic variations to gauge how patients might metabolize medications.
“This isn’t typically on the radar of frontline clinicians,” he remarked.
Udell explained that for numerous conditions, doctors can prescribe a treatment, observe the patient’s response, and adjust as needed, often without serious ramifications. This approach may be more feasible than routinely screening for genetic variations.
He also raised concerns regarding whether universal testing should be prioritized when Canada’s healthcare system is facing difficulties in delivering fundamental services.
“We’re just trying to ensure everyone has a family doctor,” he stated.
Beyond the costs associated with testing, Udell mentioned that clinicians would require access to genetic test results and the capability to interpret them properly.
Empey concurred that establishing routine genetic testing would necessitate considerable investment in training, infrastructure, and new systems to facilitate result sharing among healthcare providers.
“The scientific rationale is robust for many medications. The challenge for implementation, however, leans more towards economic, procedural, and educational aspects,” he said.
For the time being, Empey encourages patients to inquire with their doctors or pharmacists about the potential benefits of genetic testing and to share any relevant results with them.
Udell cautioned that private testing may become more prevalent for patients who can afford it, “but that won’t assist those who cannot afford the testing.”
